| Clinical data | |
|---|---|
| Other names | MEDI-0382 | 
| Routes of administration | Subcutaneous injection | 
| ATC code | 
 | 
| Legal status | |
| Legal status | 
 | 
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C167H252N42O55 | 
| Molar mass | 3728.092 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Cotadutide is an experimental drug for the treatment of type 2 diabetes mellitus. It lowers blood glucose levels by mimicking the human hormones glucagon-like peptide 1 and glucagon, which play a role in blood sugar regulation. The drug is a peptide that is injected under the skin.[1][2]
Cotadutide is in Phase II clinical trials as of February 2021.[3] Cotadutide, a therapeutic agent, was undergoing Phase II clinical trials. This stage of trials typically involves evaluating the drug's effectiveness and further assessing its safety in a larger group of participants, compared to earlier phases.
See also
References
- ↑ Parker VE, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, et al. (March 2020). "Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist". The Journal of Clinical Endocrinology and Metabolism. 105 (3): 803–820. doi:10.1210/clinem/dgz047. PMID 31608926. S2CID 204546248.
- ↑ Henderson SJ, Konkar A, Hornigold DC, Trevaskis JL, Jackson R, Fritsch Fredin M, et al. (December 2016). "Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates". Diabetes, Obesity & Metabolism. 18 (12): 1176–1190. doi:10.1111/dom.12735. PMC 5129521. PMID 27377054.
- ↑ "Cotadutide". ClinicalTrials.gov. Retrieved 2021-02-18.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.